



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/707,730	
			Filing Date	November 6, 2000	
			First Named Inventor	HILL, CRAIG	
			Art Unit	1647	
			Examiner Name	LANDSMAN, ROBERT S.	
Sheet	1	of	3	Attorney Docket Number	ASIL-002CIP

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code* (if known)				
		US-				
		US-				
		US-				
		US-				
		US-				


FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ² -Number ³ -Kind Code ⁴ (if known)					

OTHER ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BL		AGARWAL, et al., "Effects of dexamethasone (DEX) on growth factor and neurotrophin mRNA expression by cultured human trabecular meshwork cells", IOVS (March 15, 1999) vol. 40, no. 4, pp. S667 (Ann Mtg. of the Assoc for Research in Vision and Ophthalmology Fort Lauderdale, Florida, USA May 9-14, 1999)	
		GONZALEZ, et al., "Glucocorticoid regulation of motoneuronal parameters in rats with spinal cord injury", Cellular and Molecular Neurobiology, (Oct., 1999) vol. 19, no. 5, pp. 597-611.	
		NEMOTO, et al., "A possible mechanism of TPA-mediated downregulation of neurotrophin-3 gene expression in rat cultured vascular smooth muscle cells", Molecular Brain Research, (May 7, 1999) vol. 68, no. 1-2, pp. 186-189.	
		SMITH, et al., "Regulation of NGFI-A (Egr-1) gene expression by the POU domain transcription factor Brn- 3a", Brain Research, Molecular Brain Research, (1999 Dec. 10) 74 (1-2) 117-25.	
		SHI, et al., "Dexamethasone induces hypertrophy of developing medial septum cholinergic neurons: potential role of nerve growth factor", Journal of Neuroscience, (Nov. 15, 1998) vol. 18, no. 22, pp. 9326-9334.	

Examiner Signature		Date Considered	10.22.04
-----------------------	--	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (05-03)
Approved for use through 04/30/2003. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO		Complete if Known			
		Application Number	09/707,730		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	November 6, 2000		
		First Named Inventor	HILL, CRAIG		
		Art Unit	1647		
		Examiner Name	LANDSMAN, ROBERT S.		
Sheet	2	of	3	Attorney Docket Number	ASIL-002CIP

BL	YANG, et al., "Dexamethasone inhibits ischemia-induced transient reduction of neurotrophin-3 mRNA in rat hippocampal neurons", Neuroreport, (Oct. 26, 1998) vol. 9, no. 15, pp. 3477-3480.	
	VERITY, et al., "Regulation of glial cell line-derived neurotrophic factor release from rat C6 glioblastoma cells", Journal of Neurochemistry, (Feb. 1998) vol. 70, no. 2, pp. 531-539.	
	BRANDOLI, et al., "Dexamethasone decreases P75NTR expression in injured spinal cord", Society for Neuroscience Abstracts, (1998) vol. 24, no. 1-2, pp. 290 (28 th Ann Mtg. of the Society for Neuroscience, Part 1)	
	PRODANOV, et al., "Pharmacology of apoptosis in the central nervous system", Farmatsiya, (Sofia) (1998), 45(2), 31-38.	
	FINK JR., et al., "Effect of glucocorticoid on NGF-stimulated TRKA signaling in PC12 cells", Society for Neuroscience Abstracts, (1997) vol. 23, no. 1-2, pp. 1702 (27 th Ann Mtg. of the Society for Neuroscience, New Orleans, Louisiana, USA October 25-30, 1997)	
	SEIDL, et al., "Expression of nerve growth factor and neurotrophin receptors in testicular cells suggest novel roles for neurotrophins outside the nervous system", Reproduction Fertility and Development, (1996) vol. 8, no. 7, pp. 1075-1087.	
	BARBANY, "Modulation of neurotrophins and their receptors by adrenal steroids", CNS Neurotransmitters and Neuromodulators: Neuroactive Steroids (1996), 113-125.	
	SCULLY, et al, "Neurotrophin expression modulated by glucocorticoids and oestrogen in immortalized hippocampal neurons", Molecular Brain Research, (1995) vol. 31, no. 1-2, pp. 158-164.	
	HIGAKI, et al., "Neurotrophin ^R inhibits lipopolysaccharide-induced nitric oxide production in cultured human endothelial cells", Cell structure and function, (1994) vol. 19, no. 6, pp. 555 (47 th Ann Mtg. of the Japan Society for Cell Biology, Nagasaki, Japan, September 28-30, 1994).	
	KONONEN, et al., "Neurotrophins and their receptors in the rat pituitary gland: regulation of BDNF and <i>trk B</i> mRNA levels by adrenal hormones", Molecular Brain Research, (1994) vol. 27, no. 2, pp. 347-354.	
	LINDHOLM, et al., "Glucocorticoids and neurotrophin gene regulation in the nervous system", Annals of the New York Academy of Sciences, (1994 Nov. 30) 746, 195-202.	
	JELSMA, et al., "Different forms of the neurotrophin receptor <i>trk B</i> mRNA predominate in rat retina and optic nerve", Journal of Neurobiology, (1993) vol. 24, no. 9, pp. 1207-1214.	

Examiner Signature	<i>Laurel</i>	Date Considered	10.22.04
--------------------	---------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/707,730		
		Filing Date	November 6, 2000		
		First Named Inventor	HILL, CRAIG		
		Art Unit	1647		
		Examiner Name	LANDSMAN, ROBERT S.		
Sheet	3	of	3	Attorney Docket Number	ASIL-002CIP

✓	BARBANY, et al., "Adrenalectomy attenuates kainic acid-elicited increases of messenger RNAs for neurotrophins and their receptors in the rat brain", Neuroscience, (1993) vol. 54, no. 4, pp. 909-922.	
	COSI, et al., "Glucocorticoids depress activity-dependent expression of BDNF mRNA in hippocampal neurons", Neuroreport, (1993) vol. 4, no. 5, pp. 527-530.	
	SCULLY, et al., "Modulation of neurotrophin expression by glucocorticoids in immortalized hippocampal neurons", Society for Neuroscience Abstract, (1993) vol. 19, no. 1-3, pp. 256 (23 rd Ann Mtg. of the Society for Neuroscience, Washington D.C., USA, November 7-12, 1993).	
	SCULLY, et al., "glucocorticoid modulation of neurotrophin expression in immortalized mouse hippocampal neurons", Neuroscience Letters, (1993) vol. 155, no. 1, pp. 11-14.	
✓	BARBANY, et al., "Regulation of Neurotrophin mRNA Expression in the rat brain by glucocorticoids", Eur J Neurosci, (1992) 4 (5) 396-403.	

Examiner Signature	<i>Landman</i>	Date Considered	10.22.04
--------------------	----------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	09/707,730	
			Filing Date	November 6, 2000	
			First Named Inventor	HILL, CRAIG	
			Art Unit	1647	
Examiner Name	LANDSMAN, ROBERT S.				
Sheet	1	of	1	Attorney Docket Number	ASIL-002CIP

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
<i>M</i>		US- 5,389,623		02-14-1995		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
<i>M</i>		WO00/37103		06-29-2000	Xavos		
		WO01/91798(A2)		12-06-2001	Universite Catholique De Louvain		
		WO97/37966		10-16-1997	Vical Incorporated		

Examiner Signature	<i>e. Decker</i>	Date Considered	10.22.04
-----------------------	------------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.